| Name | Title | Contact Details |
|---|
We are harnessing the power of the immune system to target some of the most challenging solid tumor malignancies.
Clementia is a biopharmaceutical company that is focused on exploiting the science of novel retinoic acid receptor gamma agonists to address bone disease. Our lead program is palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).
The greatest health threats require more than an all-or-nothing approach. Nano represents a multi-layered set of solutions to usher in a new era in proactive, persistent health protection.
PolarityTE, is the owner of a novel regenerative medicine and tissue engineering platform developed and patented by Denver Lough MD, PhD. This radical and proprietary technology employs a patients` own cells for the healing of full-thickness functionally-polarized tissues. If clinically successful, the PolarityTE platform will be able to provide medical professionals with a truly new paradigm in wound healing and reconstructive surgery by utilizing a patient`s own tissue substrates for the regeneration of skin, bone, muscle, cartilage, fat, blood vessels and nerves. It is because PolarityTE uses a natural and biologically sound platform technology, which is readily adaptable to a wide spectrum of organ and tissue systems, that the company and its world-renowned clinical advisory board, are poised to drastically change the field and future of translational regenerative medicine.
Leading Biospecimen Provider of human bone marrow, cord blood, peripheral blood, Leukopaks, Mobilized Leukopaks, and more. Click to visit our website!